Where Is Hemophilia Most Common In The World?

Quick Fact: Hemophilia pops up most often in populations with long genetic histories, and Northern Europe—especially Iceland, Sweden, and Denmark—takes the top spot. Rates there hit 12–14 cases per 100,000 males. Globally, about 1 in 5,000 male births involves Hemophilia A, while Hemophilia B shows up in 1 in 20,000.

Where does hemophilia show up most often?

Hemophilia isn’t randomly distributed—it’s tied to genetics, migration, and historical population bottlenecks. The condition comes from mutations in the F8 or F9 genes on the X chromosome, which is why males are far more likely to have it. Places like Iceland or parts of Scandinavia show higher rates thanks to founder effects—when a small group of settlers passed the mutation down through generations. Meanwhile, countries with more genetic mixing, like the U.S. or Brazil, tend to have rates closer to the global average, though some ethnic groups still show higher numbers.

What’s the geographic breakdown of hemophilia cases?

Why does hemophilia appear more in some places than others?

Hemophilia’s spread comes down to genetics and history. When a small group of settlers—like Iceland’s early Vikings—carried a mutation, their descendants ended up with higher rates. That’s the founder effect in action. Meanwhile, countries with lots of genetic mixing, like the U.S., have rates closer to the global average but still see pockets of higher incidence in certain ethnic groups. Honestly, this is one of those cases where geography really shapes biology.

What’s the history behind hemophilia’s geographic patterns?

Queen Victoria’s family helped give hemophilia its infamous nickname. Her son Leopold died of a brain hemorrhage at 31, and the mutation spread through European royalty—even reaching Russia’s last tsar, Nicholas II. But the story doesn’t end there. In 2026, scientists are still figuring out why some groups carry heavier burdens. Take the Amish communities in Pennsylvania, for example. Their rates are nearly double the U.S. average because of a closed gene pool. Meanwhile, in Africa, hemophilia often goes untreated, and life expectancy for severe cases hovers around 40–50 years—a huge contrast to the 60+ years seen in well-managed regions like Sweden.

Which countries have the best hemophilia care?

If you’re looking for top-tier hemophilia care, Northern Europe is where you want to be. Iceland, Sweden, and Denmark not only have high rates of the condition but also excellent screening and treatment programs. Newborn males in Iceland, for instance, get tested within days of birth, and treatment centers are everywhere. Now, compare that to places like Nigeria or Pakistan, where there are fewer than 10 hemophilia treatment centers combined. Families there often have to rely on imported clotting factors or risky alternatives. That’s a massive gap in care.

What should travelers know about hemophilia hotspots?

For travelers or expats, knowing where hemophilia is most common can save you a lot of headaches. In Iceland, for example, newborn screening happens within days, and treatment is easy to access. But head to a country like Nigeria or Pakistan, and you’ll find fewer than 10 treatment centers combined. Families there often have to import clotting factors or use risky substitutes. If you’re planning a long-term stay in a high-prevalence area, do your homework. Some regions offer gene therapy trials, while others barely have basic diagnostics. For U.S. expats, the CDC’s travel guidelines recommend carrying a medical alert card and scoping out nearby treatment centers before you leave.

How does hemophilia prevalence compare between Hemophilia A and B?

Globally, Hemophilia A shows up in about 1 in 5,000 male births, while Hemophilia B appears in 1 in 20,000. That’s a big difference. In places like Iceland or Sweden, Hemophilia A rates hit 12–14 per 100,000 males, with Hemophilia B trailing at 2–3 per 100,000. The gap comes down to how the mutations work—F8 gene issues (Hemophilia A) are simply more common than F9 gene issues (Hemophilia B).

Are there any surprises in the data?

You’d think a country like Japan—with its advanced healthcare system—would have higher rates, but it actually sits at 7.5 per 100,000 males for Hemophilia A. That’s lower than the U.S. or Scandinavia. The reason? Improved diagnostics are catching milder cases that might have gone unnoticed in the past. Meanwhile, Sub-Saharan Africa’s numbers look artificially low at 5.4 per 100,000 males for Hemophilia A and 1.2 for Hemophilia B. In reality, hemophilia is probably underdiagnosed there because of limited access to testing and treatment.

How do founder effects influence hemophilia rates?

Founder effects happen when a small group of settlers—like Iceland’s early Vikings—carry a genetic mutation. Their descendants end up with higher rates because the mutation gets passed down through generations. That’s exactly what’s happening in Iceland, where the rate hits 14.2 per 100,000 males for Hemophilia A. The same pattern shows up in other isolated populations, like the Amish in Pennsylvania. It’s a powerful reminder of how history shapes genetics.

What role does migration play in hemophilia spread?

Migration does spread hemophilia, but it doesn’t always increase rates in the same way founder effects do. When people move, they bring their genes with them, which can introduce mutations to new areas. That’s why you see pockets of higher incidence in places like the U.S., where certain ethnic groups have European ancestry. But isolated groups—like Iceland’s early settlers—still end up with the highest concentrations because the mutation gets passed down without much mixing.

How does hemophilia impact life expectancy in different regions?

Where you live makes a huge difference if you have hemophilia. In Sweden, Denmark, or Iceland, life expectancy for severe cases often hits 60+ years thanks to early screening, treatment access, and gene therapy options. But head to Sub-Saharan Africa, and life expectancy for severe cases drops to 40–50 years. The difference comes down to healthcare resources—diagnostics, clotting factors, and specialized care are far more available in Northern Europe.

Are there any ethnic groups with unusually high rates?

Some groups stand out for their higher rates. The Amish communities in Pennsylvania, for example, have rates nearly double the U.S. average because of a closed gene pool. Meanwhile, in the U.S. Midwest and Northeast, white populations—especially those with European ancestry—show higher rates than other groups. It’s all about genetics and history.

What’s the future of hemophilia treatment in high-prevalence areas?

The future looks bright in places like Iceland and Sweden, where gene therapy trials are already underway. These regions combine high rates of hemophilia with top-tier healthcare, making them ideal testing grounds for new treatments. But in under-resourced areas—like Sub-Saharan Africa or parts of South Asia—progress is slower. Many places still struggle with basic diagnostics, let alone cutting-edge therapies. That’s a gap we’ll need to close if we want to improve outcomes everywhere.